Ciglitazone
Ciglitazone is a potent and selective PPARγ agonist (EC50=3 μM) . Ciglitazone inhibits proliferation and differentiation of th17 cells. Ciglitazone is a hypoglycemic agent orally active in the obese-hyperglycemic animal models. Ciglitazone induces apoptosis accompanied by activation of p38 MAPK and nuclear translocation of apoptosis inducing factor (AIF) in opossum kidney (OK) renal epithelial cells[1][2][3][4].
Product Specifications
CAS Number
[74772-77-3]
Product Name Alternative
ADD-3878; U-63287
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
PPAR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/ciglitazone.html
Purity
99.74
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N1)SC(CC2=CC=C(OCC3(C)CCCCC3)C=C2)C1=O
Molecular Formula
C18H23NO3S
Molecular Weight
333.45
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items